Woodline Partners’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.9M Hold
723,163
0.04% 475
2026
Q1
$12.9M Hold
723,163
0.05% 449
2025
Q4
$19.5M Hold
723,163
0.08% 320
2025
Q3
$21.9M Sell
723,163
-523,163
-42% -$16.7M 0.1% 261
2025
Q2
$33.3M Buy
+1,246,326
New +$33.6M 0.18% 165

Other funds holding CAI

Woodline Partners's CAI Position: Q2 2026 in Review

Woodline Partners held its Caris Life Sciences (CAI) position steady in Q2 2026 at 723,163 shares worth $12.9M. The position accounts for 0.04% of the portfolio, ranked #475.

Woodline Partners first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $33.3M in Q2 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Woodline Partners held 723,163 shares of Caris Life Sciences worth $12.9M as of Q2 2026.
  • Woodline Partners left its Caris Life Sciences share count unchanged in Q2 2026.
  • Caris Life Sciences made up 0.04% of Woodline Partners's portfolio in Q2 2026, its #475 holding.
  • Woodline Partners first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Woodline Partners's Caris Life Sciences position peaked at $33.3M in Q2 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.